With this acquisition, Atrium will take over a manufacturing plant and process that is approved by different regulatory bodies in countries where Wobenzym products are sold.
Atrium distributes its products mainly in the healthcare practitioner and health food and specialized store channels, with a primary focus in North America and Europe.
The acquisition is aimed at obtaining two enzymes, which are in relatively short supply worldwide in the quality required for the formulation of Wobenzym products.